In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Nor polypharmacy nor length-of-stay are correlated with survival in old old patients (> 85 years) with chronic heart failure

Session Poster session 1 Saturday 08:30 -17:30

Speaker Antoniu Octavian Petris

Congress : Heart Failure 2015

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure
  • Session type : Poster Session
  • FP Number : P231

Authors : A Petris (Iasi,RO), I Tudorancea (Iasi,RO), G Tatu-Chitoiu (Bucharest,RO), I Costache (Iasi,RO)

15 views

Authors:
A Petris1 , I Tudorancea1 , G Tatu-Chitoiu2 , I Costache1 , 1Universitatea de Medicina si farmacie "Gr.T. Popa" - Iasi - Romania , 2Emergency Clinical Hospital Floreasca - Bucharest - Romania ,

Citation:
European Journal of Heart Failure Abstracts Supplement ( 2015 ) 17 ( Supplement 1 ), 47

Background: For the old old patients (pts) with congestive heart failure the use of combinations of drugs can easily lead to a sort of "evidence-based" polypragmasie and a longer length-of-stay (LOS).

Methods: We analyzed a lot of 125 pts older than 85 years (mean 87.43 +/- 2.54 years, range 85-99 years), 53.6% male, enrolled consecutively between January 2011 - December 2012, diagnosed with congestive heart failure. We have compared some features of two subgroups: survivors (S=112 pts) vs deceased (D=13 pts).

Results: The old old patients group included patients diagnosed mainly with ischemic dilated cardiomyopathy (57/45.6%), alcoholic cardiomyopathy (4/3.2%), mixed (26/20.8%), hypertensive cardiopathy (31/30.4%), in NYHA class II (61/48.8%), class III (55/44%) and class IV (9/7.2%), with length of hospitalization of 8.10+/-3.98 days and the rate of re-hospitalization 6.4% and the death rate 10.4%. Number of drugs taken was 5.53+/-1.86 in S group vs 5.85+/-1.86 in D group (p = 0.421) and the length-of-stay was 8.18+/-3.79 in S group vs 7.38+/-5.53 in D group (p = 0.06). There were significant differences between group S vs D in: NYHA class, non- smoker status, hemoglobin level (12.57+/-1.92 vs 11.20+/-1.87 g/dl, p = 0.017), blood urea nitrogen (58.38+/-28.92 vs 77.30+/-47.99 mg/dl, p = 0.04), serum uric acid (6.32+/-1.99 vs 8.91+/-4.27 mg/dl, p = 0.001), serum sodium (139.97+/-4.55 vs 136.69+/-7.12 mg/dl, p = 0.024) and BNP (524.49+/-116.87 vs 2480.75+/-951.99 pg/ml, p = 0.001).

Conclusions: The number of drugs given to old old patients has not proven to reduce the length of stay, the rate of death and re-hospitalization. Hyponatremia, anemia and increased urea and serum uric acid are associated with increased mortality of old old patients.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are